AHK-Cu is the copper complex of L-alanyl-L-histidyl-L-lysine, written in the 2007 paper as "L-alanyl-L-histidyl-L-lysine-Cu2+ (AHK-Cu)".1 The app describes it as a copper-binding tripeptide studied mainly for hair and skin, used predominantly topically or as a cosmetic, with limited human data. The app grades the evidence as emerging. Searches of PubMed on 16 November 2026 for "AHK-Cu" and for "AHK copper tripeptide hair" each returned one record, the 2007 laboratory study by Pyo and colleagues.1 A search of ClinicalTrials.gov for "AHK-Cu" returned one registry entry, NCT07888595, in which AHK-Cu is one of five peptides in a topical serum.2 A search of DailyMed for "AHK-Cu" on 16 November 2026 returned no drug label.

2

How it works

Sources in this part

  1. 1Pyo et al., 2007

The 2007 paper's summary describes dermal papilla cells as "specialized fibroblasts, which are important in the morphogenesis and growth of hair follicles".1 The authors measured apoptosis by Annexin V and propidium iodide labeling with flow cytometry, and report that at 10⁻⁹ M "the ratio of Bcl-2/Bax was elevated, and the levels of the cleaved forms of caspase-3 and PARP were reduced".1 They write that the study "proposed that AHK-Cu promotes the growth of human hair follicles, and this stimulatory effect may occur due to stimulation of the proliferation and the preclusion of the apoptosis of DPCs".1 In the same summary, the decrease in the number of apoptotic dermal papilla cells at 10⁻⁹ M was not statistically significant.1

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~4 h
Bioavailability
90%
Typical dose
1–3 mg/day
Route
SubQ, topical
Time to peak
~0.5 h
Table 3.1Half-life and pharmacokinetics4 rows
ParameterApp's figureFigure in the sources
Half-life~4 hNo figure from a study or label identified in the searches above
Bioavailability90%No figure from a study or label identified in the searches above
Time to peak~0.5 hNo figure from a study or label identified in the searches above
RouteSubQ, topicalThe registry entry lists a topical serum applied to skin sites; neither cited source gives a subcutaneous route for AHK-Cu2

The app's pharmacokinetic figures therefore have no figure from a study or label beside them here; the 2007 study was a culture study and its PubMed summary reports none.1

4

Human studies

No completed trial or posted result of AHK-Cu in people was identified in PubMed or ClinicalTrials.gov; the one registry entry that lists it compares serum-applied skin sites with untreated sites on the same participants.2

Table 4.1Human studies2 rows
Study and yearDesignPeopleDose and lengthMain result
Pyo and colleagues, Archives of Pharmacal Research 20071Laboratory study of human hair follicles ex vivo and cultured dermal papilla cells; group sizes not given in the PubMed recordNo participants; human follicles and cellsAHK-Cu 10⁻¹² to 10⁻⁹ M; culture length not given in the PubMed recordStimulated follicle elongation and cell proliferation; fewer apoptotic cells at 10⁻⁹ M, but the decrease was not statistically significant
NCT07888595, Frontiers in Bioscience Research Institute and Aging, registered 20262Single-group, unmasked, early phase 1; enrolling by invitation; treated skin sites compared with untreated sites on the same participantHealthy volunteers aged 50 to 100 yearsTopical serum of five peptides including AHK-Cu at approximately 1-3 mg/mL, with systemic agents such as metformin, chloroquine and ivermectin in the same study; time frame 4 weeks; estimated completion 14 October 2028No result reported; the entry has "Has Results: undefined"; primary outcome is biological age from skin, hair, saliva and blood clocks

Deeper analysis: the 2007 hair follicle study

Pyo and colleagues, whose first-author affiliation in PubMed is the Department of Dermatology, College of Medicine, Seoul National University, published the study in Archives of Pharmacal Research in 2007.1 The study evaluated "the effects of L-alanyl-L-histidyl-L-lysine-Cu2+ (AHK-Cu) on human hair growth ex vivo and cultured dermal papilla cells".1 It reports that "AHK-Cu (10(-12) - 10(-9) M) stimulated the elongation of human hair follicles ex vivo and the proliferation of DPCs in vitro".1 At 10⁻⁹ M, AHK-Cu "reduced the number of apoptotic DPCs, but this decrease was not statistically significant".1 The PubMed record gives no p-values or intervals for the elongation or proliferation findings, no number of follicles, donors or replicates, and no adverse event or toxicity result.1 The record lists the publication type "Research Support, Non-U.S. Gov't" and no grant or sponsor, and gives no authors' statement of limitations or competing interests; the full text was not available.1

Deeper analysis: registry entry NCT07888595

The registry entry names Frontiers in Bioscience Research Institute and Aging as lead sponsor and describes "a prospective, single-group interventional study with two treatment components, systemic and topical".2 Its topical component is "an aqueous serum of small, water-soluble anti-aging peptides" that includes GHK-Cu, AHK-Cu, Epitalon, PGP and CLV, and the same study also lists systemic agents such as metformin, low-dose chloroquine and ivermectin, so a finding from the entry would not be specific to AHK-Cu.2 The entry's start date of 21 October 2026 is marked as estimated, and no result or adverse event data are posted.2

5

Doses reported in studies and on labels

Table 5.1Doses reported in studies and on labels2 rows
SourcePreparationAmount reportedSetting
2007 laboratory study1AHK-Cu in culture10⁻¹² to 10⁻⁹ MHuman hair follicles ex vivo and dermal papilla cells; not a dose for people
NCT078885952Aqueous serum of five peptides including AHK-CuApproximately 1-3 mg/mL, applied to defined skin sitesRegistry description of a planned topical component; a concentration, not a daily amount

The app's typical dose of 1–3 mg/day is in different units from the registry's 1-3 mg/mL concentration, and neither source gives a daily amount of AHK-Cu.

6

Regulatory and anti-doping status

A search of DailyMed on 16 November 2026 for "AHK-Cu" returned no label. The WADA Prohibited List and regulators' documents were not searched for AHK-Cu, so no anti-doping status is given.

7

What is not known

No half-life, bioavailability, time to peak or other pharmacokinetic measurement of AHK-Cu was identified in PubMed, ClinicalTrials.gov or DailyMed. No study of AHK-Cu reporting safety, adverse effects or toxicity was identified in PubMed. No study of AHK-Cu in animals was identified in the same PubMed searches.

What is AHK-Cu?

AHK-Cu is the copper complex of L-alanyl-L-histidyl-L-lysine.1

What is the half-life of AHK-Cu?

The app lists a half-life of about 4 hours, and no figure from a study or label was identified.

What is the bioavailability of AHK-Cu?

The app lists 90%, and no figure from a study or label was identified.

Has AHK-Cu been tested in people?

No completed trial or posted result of AHK-Cu in people was identified in PubMed or ClinicalTrials.gov. A registry entry, NCT07888595, lists AHK-Cu as one of five peptides in a topical serum and reports no results.2

What did the 2007 AHK-Cu hair study find?

It reported that AHK-Cu at 10⁻¹² to 10⁻⁹ M stimulated the elongation of human hair follicles ex vivo and the proliferation of dermal papilla cells in vitro.1 The decrease in apoptotic dermal papilla cells at 10⁻⁹ M was not statistically significant.1

Is AHK-Cu the same as GHK-Cu?

The registry entry NCT07888595 lists them as separate peptides, GHK-Cu at about 404 Da and AHK-Cu at about 418 Da.2

10

References

  1. Pyo HK, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res 2007;30(7):834-9. PMID 17703734
  2. Frontiers in Bioscience Research Institute and Aging. Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks. ClinicalTrials.gov NCT07888595, record posted October 2026. NCT07888595